Home › Trial NCT06970912
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
- Trial IDNCT06970912
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorPeking University People's Hospital
- Enrollment393
- Start date2025-08-01
- ConditionsHormone Receptor-Positive Breast Cancer · High-risk Breast Cancer · Early-Stage Breast Cancer · HER2-negative Breast Cancer · ctDNA Monitoring · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.